Clinical Trial Update: Olaparib With Ceralasertib in Recurrent Osteosarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of olaparib and ceralasertib in recurrent osteosarcoma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Ceralasertib (ceralasertib)
• Lynparza (olaparib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Osteosarcoma, Osteosarcoma Recurrent | Phase 2 | Status: ACTIVE_NOT_RECRUITING